The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 64 (elevated attention) · dilution pressure elevated · listing risk elevated · governance risk low · runway 8.9 mo · strongest signal: Near $5M MVLS floor (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway 6–12 months) coexists with live selling machinery (shelf effective, offering (424b)). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 12, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-12 filing | 25 |
| Aug 4, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-08-04 filing | 27 |
| Jul 24, 2026 | ▼ Reverse split | “reverse split” language in PRE 14A (PRE 14A) filed 2026-07-24 filing | 27 |
| Jul 17, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-07-17; 2 prior 424B filings in 12m filing | 27 |
| Jul 17, 2026 | ▼ Shelf effective | EFFECT notice 2026-07-17 filing | 21 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $1,896,114 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 30 |
| Jun 30, 2026 | ▼ Runway 6–12 months | ~8.9 months runway: liquidity $8,289,108 as of 2026-06-30, burn $11,236,622/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 25 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →